44
Participants
Start Date
April 20, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
INO-5401
INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.
INO-9012
INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.
Cellectra 2000
The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
University of Pennsylvania, Philadelphia
Collaborators (1)
Inovio Pharmaceuticals
INDUSTRY
University of Pennsylvania
OTHER